Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699123 · ClinicalTrials.gov registry record · Phase 2
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
A Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 1
- Study location
NCT04699123 is a Phase 2 study of Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Yale University. The registered enrollment target is 159 participants, below the 375-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04699123, a Phase 2 study of Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG NC318 800 mg
- DRUG NC318 400 mg
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699123
The ClinicalTrials.gov registry entry for NCT04699123 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 375-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (58% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04699123 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04699123 about?
NCT04699123 is a clinical study titled "The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer". This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
What is the current status of trial NCT04699123?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2021-02-04. Estimated completion is 2025-06-30.
What conditions does trial NCT04699123 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT04699123?
The interventions under investigation include: Pembrolizumab (DRUG), NC318 800 mg (DRUG), NC318 400 mg (DRUG).
Who is sponsoring clinical trial NCT04699123?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04699123 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
RECRUITING · Phase 2
-
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.